MT 100Treatment for Migraine
FDA Sets August 4, 2005 for Advisory Committee Meeting to Consider Tardive Dyskinesia Risk with MT 100
CHAPEL HILL, N.C., June 29, 2005 - Pozen Inc. (NASDAQ: POZN), a pharmaceutical company focused primarily on products for the treatment of migraine, acute and chronic pain and other pain-related conditions, announced today that the U.S. Food and Drug Administration (FDA) has set August 4, 2005 as the date for the meeting of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee. The Advisory Committee is expected to review the potential risk of the occurrence of an involuntary neurological movement disorder known as tardive dyskinesia with the use of Pozen's product candidate MT 100 for the treatment of migraine.
Pozen is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, Pozen has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. Pozen is also exploring the development of product candidates in other pain-related therapeutic areas.
Posted: June 2005
- POZEN Provides Results of FDA Advisory Committee Meeting on MT 100 (Naproxen Sodium and Metoclopramide Hydrochloride) - August 5, 2005
- POZEN's MT 100 To Be Reviewed by Advisory Committee in May 2005 - December 21, 2004